| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8962294 | Vaccine | 2018 | 8 Pages |
Abstract
BCG discontinuation may be warranted in intermediate burden settings, depending on the quality of vaccine protection, and the potential for refocusing on other TB control activities for earlier detection and treatment.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Han Fu, Hsien-Ho Lin, Timothy B. Hallett, Nimalan Arinaminpathy,